Profil
Judith Segall is the founder of Lineage Cell Therapeutics, Inc. which was founded in 1990.
She held the title of Vice President-Administration from 2016 to 2019.
Currently, she is the Secretary & Director-Administration at AgeX Therapeutics, Inc. since 2017.
Ms. Segall has also worked as Secretary & Director at Asterias Biotherapeutics, Inc. and as Secretary at OncoCyte Corp.
Ms. Segall received her undergraduate degree from the University of California, Berkeley in 1989.
Anciens postes connus de Judith Segall
| Sociétés | Poste | Fin |
|---|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Founder | 01/08/2019 |
| AGEX THERAPEUTICS, INC. | Chief Administrative Officer | - |
| ONCOCYTE CORPORATION | Corporate Secretary | - |
| ASTERIAS BIOTHERAPEUTICS INC | Director/Board Member | - |
Formation de Judith Segall
| University of California, Berkeley | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| ONCOCYTE CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
AgeX Therapeutics, Inc.
 AgeX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA. | Health Technology |
